Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H12N2O |
Molecular Weight | 176.2151 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1[C@@H](CCC1=O)C2=CN=CC=C2
InChI
InChIKey=UIKROCXWUNQSPJ-VIFPVBQESA-N
InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1
Molecular Formula | C10H12N2O |
Molecular Weight | 176.2151 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://cancercontrol.cancer.gov/brp/tcrb/monographs/7/m7_7.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26972290
Curator's Comment: description was created based on several sources, including:
https://cancercontrol.cancer.gov/brp/tcrb/monographs/7/m7_7.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26972290
Cotinine is a product formed after the chemical nicotine enters the body. Measuring cotinine in people’s blood is the most reliable way to determine exposure to nicotine for both smokers and nonsmokers exposed to environmental tobacco smoke. Cotinine is safe, non-addictive and has pharmacokinetic properties adequate for therapeutic use. Research has shown that cotinine has antipsychotic, anxiolytic, and antidepressant properties and modulates the serotonergic, cholinergic and dopaminergic systems. Cotinine behaves as a positive allosteric modulator of the nicotinic acetylcholine receptors and has anti-inflammatory effects. Cotinine is under investigation as an agent for the treatment of depression, PTSD, schizophrenia, Alzheimer's disease and Parkinson's disease.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24713149 | https://www.ncbi.nlm.nih.gov/pubmed/11974
Curator's Comment: Known to be CNS penetrant in mouse. Human data not available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Nicotinic acetylcholine receptors alpha3/alpha6/beta2 (Saimiri sciureus) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18305015 |
236.0 µM [EC50] | ||
Target ID: Nicotinic acetylcholine receptors alpha4/beta2 (Saimiri sciureus) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18305015 |
495.0 µM [EC50] | ||
Target ID: CHEMBL2492 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23087643 |
175.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Determination of coumarin metabolism in Turkish population. | 2001 Apr |
|
Factors associated with discrepancies between self-reports on cigarette smoking and measured serum cotinine levels among persons aged 17 years or older: Third National Health and Nutrition Examination Survey, 1988-1994. | 2001 Apr 15 |
|
Novel liquid chromatographic-tandem mass spectrometric methods using silica columns and aqueous-organic mobile phases for quantitative analysis of polar ionic analytes in biological fluids. | 2001 Apr 25 |
|
Osteogenic protein-1 overcomes the inhibitory effect of nicotine on posterolateral lumbar fusion. | 2001 Aug 1 |
|
Smoking reduction in smokers compliant to a smoking cessation trial with nicotine patch. | 2001 Feb |
|
Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. | 2001 Feb |
|
[Smoking in adolescents, saliva cotinine concentrations and respiratory disease]. | 2001 Feb |
|
Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results. | 2001 Feb |
|
Tobacco hypersensitivity and environmental tobacco smoke exposure in a pediatric population. | 2001 Jan |
|
Pharmacokinetics of nicotine in healthy elderly people. | 2001 Jan |
|
Chronic maternal smoking and cord blood amino acid and enzyme levels at term. | 2001 Jan |
|
Does passive smoking increase the frequency of health service contacts in children with asthma? | 2001 Jan |
|
Effects of nicotine and cotinine on porcine arterial endothelial cell function. | 2001 Jan |
|
Nicotine yield from machine-smoked cigarettes and nicotine intakes in smokers: evidence from a representative population survey. | 2001 Jan 17 |
|
Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. | 2001 Jul |
|
Oltipraz chemoprevention trial in Qidong, People's Republic of China: results of urine genotoxicity assays as related to smoking habits. | 2001 Jul |
|
Saliva cotinine as indicator of cigarette smoking in pregnant women. | 2001 Jul |
|
Trends in the smoking habits of young adults with diabetes. | 2001 Jul |
|
Prevalence of nicotine consumption in drug deaths. | 2001 Jul 15 |
|
Nicotine produces selective degeneration in the medial habenula and fasciculus retroflexus. | 2001 Jul 6 |
|
An integrated approach to prenatal smoking cessation interventions. | 2001 Jul-Aug |
|
Nicotine metabolism and CYP2A6 allele frequencies in Koreans. | 2001 Jun |
|
CYP1B1 expression in human lung. | 2001 Jun |
|
Quantification of nicotine, chlorpyrifos and their metabolites in rat plasma and urine using high-performance liquid chromatography. | 2001 Jun 15 |
|
Cluster randomised controlled trial to compare three methods of promoting secondary prevention of coronary heart disease in primary care. | 2001 Jun 2 |
|
Exposure to ethanol and nicotine during the brain growth spurt: spatial DMP performance in male rats. | 2001 Mar |
|
The effect of stopping smoking on cervical Langerhans' cells and lymphocytes. | 2001 Mar |
|
Science is changing! 300 chemicals and each chemical will have a fingerprint. | 2001 May |
|
Bacterial mutagenicity of some tobacco aromatic nitrogen bases and their mixtures. | 2001 May 31 |
|
Systemic nicotine exposure in tobacco harvesters. | 2001 May-Jun |
|
Personal exposures to PM(2.5) and polycyclic aromatic hydrocarbons and their relationship to environmental tobacco smoke at two locations in Greece. | 2001 May-Jun |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24713149
Mouse: 5 mg/kg during 37 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9159433
High (190 ug/ml) concentration of Cotinine significantly altered all the sperm kinetic variables in relation to the time of incubation (forward motility, velocity, linearity and beat cross-frequency). Despite the impact seen on these parameters, there was still 30% forward motility after 24 h of incubation.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:06:52 UTC 2023
by
admin
on
Wed Jul 05 23:06:52 UTC 2023
|
Record UNII |
K5161X06LL
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C73579
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
737
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
COTININE
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
7805
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
DTXSID1047576
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
854019
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
207-634-9
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
D003367
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
486-56-6
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
100000084251
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
68641
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
K5161X06LL
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
1625
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
1463348
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
M3811
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | Merck Index | ||
|
C70941
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
CHEMBL578211
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY | |||
|
SUB06811MIG
Created by
admin on Wed Jul 05 23:06:52 UTC 2023 , Edited by admin on Wed Jul 05 23:06:52 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
Mediator Substance is AOX1
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY | |||
|
PARENT -> IMPURITY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||